IL13 and asthma: The alpha subunit of the IL-4 receptor (dupilumab), that blocks both IL-4 and IL-13 pathways, has resulted in reduction of asthma morbidity, while the use of the anti-IL-4R failed in phase II (Eger and Bel, 2019).